The Lymphoma Channel is supported with funding from AstraZeneca (Diamond), BMS (Gold), Johnson & Johnson (Gold), Takeda (Silver) and Galapagos (Bronze).
VJHemOnc is an independent medical education platform. Supporters, including channel supporters, have no influence over the production of content. The levels of sponsorship listed are reflective of the amount of funding given to support the channel.
Welcome to The Indolent B-Cell Lymphoma Channel
VJHemOnc brings you the most exciting research, directly from the experts. The Indolent B-Cell Lymphoma Channel covers all of the latest updates presented at major international congresses in the form of video interviews, podcasts and roundtable discussions.
Alongside updates from key clinical trials of CAR-T therapies, monoclonal antibody therapies and BTK inhibitors across the spectrum of indolent B-cell lymphomas, including follicular lymphoma, Waldenström’s macroglobulinemia and more, The Indolent B-Cell Lymphoma Channel covers advances in therapy optimization, the management of therapy-related toxicities and the latest findings from real-world data studies.
Follicular
Lymphoma
View all
The Lymphoma Channel is supported with funding from AstraZeneca (Diamond), BMS (Gold), Johnson & Johnson (Gold), Takeda (Silver) and Galapagos (Bronze).
Diamond Supporter
Gold Supporter
Silver Supporter
Bronze Supporter
VJHemOnc is an independent medical education platform. Supporters, including channel supporters, have no influence over the production of content. The levels of sponsorship listed are reflective of the amount of funding given to support the channel.
If you are interested in becoming a supporter of The Lymphoma Channel, please contact us.
